Dr. Kaliappanadar Nellaiappan has more than 25 years of experience in the development of new drugs and therapeutic agents. He has led various teams to develop more than 100 dosage formulations throughout his career and continues to head a product development group at CuriRx since 2012.

Nells has also been involved in developing novel drug delivery systems for both hydrophobic and hydrophilic molecules, including peptides, and polymer-based oral nanoparticles. He has seven approved patents, several patent applications pending, and more than 50 publications to his name.

Prior to joining CuriRx, Dr. Nellaiappan served as a senior scientist at Formatech, Inc., where he was involved in the strategic direction of formulation development and analytical method development for small molecules and biologics. Before Formatech, he worked at Mass Biologics, developing a vaccine for Shiga toxins.

Dr. Nellaiappan received his PhD from the University of Madras and received Royal Society bursary award from Oxford University. He did his post-doctoral work at UMass Boston and Boston University.

An experienced professional in analytical chemistry, formulation development and CMC of biologics and small molecules. Graduated from CUNY with a postdoctoral research fellowship at American Health Foundation, a cancer research institute, and advanced the knowledge in tobacco related chemical carcinogenesis. Published 10+ peer reviewed research articles in collaboration with scientists and physicians. Bijay joined the API industry and contributed to the development and manufacturing of active pharmaceutical ingredients and intermediates for commercial drug products.

After ten plus years in the API industry, Bijay joined the Biophannaceutical industry and developed analytical methods and formulations for peptides and proteins for Phase 1 to Phase 3 clinical trials. Subsequently engaged in supporting the product launch of the first Hep C drug to the market and supported a marketed drug for treatment of angioedema. For the past ten years Bijay has been engaged in the development of formulations for biologics such as high and low concentration of antibody, protein, oligonucleotide, AAV and small molecules for parenteral administration. During the past 20+ years, he has taken roles from a subject matter expert in analytical development, formulation development and CMC development to technical management and a leadership role to advance the project to completion by interacting with multifunctional teams across a spectrum of virtual to established drug development environment. 

Joseph brings over 20 years of versatile experience in human resources across industries such as pharmaceuticals, FMCG, manufacturing, financial services, and telecommunications. His expertise spans a wide array of HR functions, including talent management, employee development, HR operations, and organizational development.

With a focus on driving organizational growth and fostering an inclusive workplace, Joseph oversees HR programs, workforce training, employee engagement initiatives, and ensures compliance with HR regulations. He is responsible for streamlining internal services to enhance efficiency, managing HR systems, and providing strategic leadership in aligning HR practices with company goals.

Known for his people-first approach and strategic leadership, Joseph has been instrumental in creating a thriving, collaborative work environment that supports employee well-being and drives business success. His ability to integrate technology and innovation into HR practices has contributed significantly to shaping a dynamic and agile workplace culture that promotes both individual and organizational growth.

With over 25 years of experience in biopharmaceutical drug development, Doug specializes in protein expression, cell line development, process optimization (upstream and downstream), and Chemistry, Manufacturing, and Controls (CMC). His expertise spans analytical method and formulation development across biologics and small molecules. He has held leadership roles at notable companies such as MilliporeSigma, Dyax Corporation, Bristol Myers Squibb, and Pfizer.

Tim has more than 20 years of experience as an analytical method development and product characterization scientist. Tim has applied this strong technical background towards leading Analytical Development and QC teams, although he still considers himself an analytical scientist, a problem solver, as well as a leader. Throughout much of his career experience he has developed a strong background in large molecule structural characterization and methods development applied toward biotherapeutic analytical support within CMC.

Recent experiences include roles at Acceleron Pharma where he developed from a Scientist to Sr Manager roles within CMC during the growth and development of Acceleron from an early stage clinical to a commercial company. Tim has also led the Analytical Development and QC functions at both Gemini Therapeutics and Xilio Therapeutics.

Tim lives in Arlington, MA with his wife and 2 kids. He enjoys spending as much time as possible with his family; especially if it involves fishing or snowboarding!

Patricia A. Lever is a dynamic business development and marketing professional currently spearheading initiatives at CuriRx. With a unique blend of pharmaceutical technology expertise and specialized knowledge in medical device manufacturing and AI healthcare applications, Patricia brings 25 years of experience to her role.

She is recognized for her leadership, developing comprehensive go-to-market strategies and driving revenue growth through strategic partnerships and business development. Her background as a Pharmacy Technician and Master of Science degree has provided her with valuable insights into the pharmaceutical industry.

John Schaumloffel joined CuriRx as Quality Manager in 2023 after filling leadership positions in both industry and higher education. A classically trained analytical chemist focusing on atomic and molecular spectroscopy in environmental systems with a Ph.D. from Washington State University, his experience in pharma began with a focus on method development, method transfers, validation studies and research & development investigations with one of the largest generic oral dosage manufacturers in the USA. That experience translated into additional work on instrument and software qualifications and validations, with an eventual return to leadership positions at three different higher education institutions. Wanting to focus on quality outcomes and customer service, John returned to industry as a microbiology QC laboratory supervisor in the life sciences before joining CuriRx. His focus on the Quality Team has been on continuous improvement, right-the-first time initiatives in quality, and on leading CuriRx towards ISO 9001 certification.